- Home
- CMPX vs HUMA Comparison
CMPX vs HUMA Comparison
Compare CMPX & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- HUMA
- Stock Information
- Founded
- CMPX 2014
- HUMA 2004
- Country
- CMPX United States
- HUMA United States
- Employees
- CMPX N/A
- HUMA N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- HUMA Health Care
- Exchange
- CMPX Nasdaq
- HUMA Nasdaq
- Market Cap
- CMPX 229.5M
- HUMA 221.8M
- IPO Year
- CMPX N/A
- HUMA N/A
- Fundamental
- Price
- CMPX $1.82
- HUMA $1.19
- Analyst Decision
- CMPX Strong Buy
- HUMA Strong Buy
- Analyst Count
- CMPX 8
- HUMA 6
- Target Price
- CMPX $13.13
- HUMA $14.60
- AVG Volume (30 Days)
- CMPX 762.7K
- HUMA 2.8M
- Earning Date
- CMPX 05-08-2025
- HUMA 05-13-2025
- Dividend Yield
- CMPX N/A
- HUMA N/A
- EPS Growth
- CMPX N/A
- HUMA N/A
- EPS
- CMPX N/A
- HUMA N/A
- Revenue
- CMPX $850,000.00
- HUMA N/A
- Revenue This Year
- CMPX $47.65
- HUMA N/A
- Revenue Next Year
- CMPX $2,622.79
- HUMA $1,178.20
- P/E Ratio
- CMPX N/A
- HUMA N/A
- Revenue Growth
- CMPX N/A
- HUMA N/A
- 52 Week Low
- CMPX $0.77
- HUMA $1.15
- 52 Week High
- CMPX $4.08
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- CMPX 46.49
- HUMA 29.75
- Support Level
- CMPX $1.79
- HUMA $1.35
- Resistance Level
- CMPX $1.95
- HUMA $1.26
- Average True Range (ATR)
- CMPX 0.14
- HUMA 0.09
- MACD
- CMPX 0.01
- HUMA 0.03
- Stochastic Oscillator
- CMPX 29.52
- HUMA 2.78
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.